|
Synonyms: mPEG-PTH (1-34) | TransCon PTH | Yorvipath®
palopegteriparatide is an approved drug (EMA (2023), FDA (2024))
Compound class:
Peptide
Comment: Palopegteriparatide is a synthetic parathyroid hormone mimetic prodrug. Structurally it is an N-terminally PEGylated fragment of amino acids 1-34 of the mature human peptide (84 aa) [1]. Palopegteriparatide is inactive at the PTH receptor until the peptide-PEG linker is cleaved, releasing the active PTH(1-34) peptide.
|
| No information available. |
Summary of Clinical Use  |
| Palopegteriparatide is a PTH replacement therapy that is authorised as a sustained-release prodrug to treat hypoparathyroidism. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT04701203 | A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Daily in Adults With Hypoparathyroidism | Phase 3 Interventional | Ascendis Pharma A/S | ||
| NCT05387070 | PaTHway CHINA TRIAL: A Trial to Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism | Phase 3 Interventional | Visen Pharmaceuticals (Shanghai) Co., Ltd. | ||
| External links |
|
For extended ADME data see the following: European Medicines Agency (EMA) |
